These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37025462)

  • 1. Treating hepatitis D with bulevirtide - Real-world experience from 114 patients.
    Dietz-Fricke C; Tacke F; Zöllner C; Demir M; Schmidt HH; Schramm C; Willuweit K; Lange CM; Weber S; Denk G; Berg CP; Grottenthaler JM; Merle U; Olkus A; Zeuzem S; Sprinzl K; Berg T; van Bömmel F; Wiegand J; Herta T; Seufferlein T; Zizer E; Dikopoulos N; Thimme R; Neumann-Haefelin C; Galle PR; Sprinzl M; Lohse AW; Schulze Zur Wiesch J; Kempski J; Geier A; Reiter FP; Schlevogt B; Gödiker J; Hofmann WP; Buggisch P; Kahlhöfer J; Port K; Maasoumy B; Cornberg M; Wedemeyer H; Deterding K
    JHEP Rep; 2023 Apr; 5(4):100686. PubMed ID: 37025462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
    Wedemeyer H; Aleman S; Brunetto M; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Ciesek S; Manuilov D; Mercier RC; Da BL; Chee GM; Li M; Flaherty JF; Lau AH; Osinusi A; Schulze Zur Wiesch J; Cornberg M; Zeuzem S; Lampertico P
    J Hepatol; 2024 Oct; 81(4):621-629. PubMed ID: 38734383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.
    Dietz-Fricke C; Degasperi E; Jachs M; Maasoumy B; Reiter FP; Geier A; Grottenthaler JM; Berg CP; Sprinzl K; Zeuzem S; Gödiker J; Schlevogt B; Herta T; Wiegand J; Soffredini R; Wedemeyer H; Deterding K; Reiberger T; Lampertico P
    Hepatology; 2024 Sep; 80(3):664-673. PubMed ID: 38478755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
    Degasperi E; Anolli MP; Uceda Renteria SC; Sambarino D; Borghi M; Perbellini R; Scholtes C; Facchetti F; Loglio A; Monico S; Fraquelli M; Costantino A; Ceriotti F; Zoulim F; Lampertico P
    J Hepatol; 2022 Dec; 77(6):1525-1531. PubMed ID: 35973578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
    Allweiss L; Volmari A; Suri V; Wallin JJ; Flaherty JF; Manuilov D; Downie B; Lütgehetmann M; Bockmann JH; Urban S; Wedemeyer H; Dandri M
    J Hepatol; 2024 Jun; 80(6):882-891. PubMed ID: 38340811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression.
    Jachs M; Panzer M; Hartl L; Schwarz M; Balcar L; Camp JV; Munda P; Mandorfer M; Trauner M; Aberle SW; Zoller H; Reiberger T; Ferenci P
    JHEP Rep; 2023 Aug; 5(8):100751. PubMed ID: 37360907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
    Hollnberger J; Liu Y; Xu S; Chang S; Martin R; Manhas S; Aeschbacher T; Han B; Yazdi T; May L; Han D; Shornikov A; Flaherty J; Manuilov D; Suri V; Asselah T; Lampertico P; Wedemeyer H; Aleman S; Richards C; Mateo R; Maiorova E; Cihlar T; Mo H; Urban S
    J Hepatol; 2023 Sep; 79(3):657-665. PubMed ID: 37120031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
    Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
    Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bulevirtide and emerging drugs for the treatment of hepatitis D.
    Xu HY; Yang JO; Chen PH; Han SB
    Expert Opin Biol Ther; 2023; 23(12):1245-1253. PubMed ID: 37853604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Real world" efficacy of bulevirtide in HBV/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy.
    Visco Comandini U; De Santis E; De Maria F; Lionetti R; Taibi C; Montalbano M; Rianda A; Piccolo P; De Ponte C; Mazzotta S; Caioli A; Garbuglia AR; Maggi F; D'Offizi G
    HIV Med; 2023 Oct; 24(10):1075-1082. PubMed ID: 37287427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
    Wedemeyer H; Aleman S; Brunetto MR; Blank A; Andreone P; Bogomolov P; Chulanov V; Mamonova N; Geyvandova N; Morozov V; Sagalova O; Stepanova T; Berger A; Manuilov D; Suri V; An Q; Da B; Flaherty J; Osinusi A; Liu Y; Merle U; Schulze Zur Wiesch J; Zeuzem S; Ciesek S; Cornberg M; Lampertico P;
    N Engl J Med; 2023 Jul; 389(1):22-32. PubMed ID: 37345876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.
    de Lédinghen V; Fougerou-Leurent C; Le Pabic E; Pol S; Alfaiate D; Lacombe K; Hilleret MN; Lascoux-Combe C; Minello A; Billaud E; Rosa I; Gervais A; Ratziu V; Ganne N; Pageaux GP; Leroy V; Loustaud-Ratti V; Mathurin P; Chas J; Jezequel C; Métivier S; Dumortier J; Arpurt JP; Asselah T; Roche B; Le Gruyer A; Valantin MA; Scholtès C; Gordien E; Tual C; Kortebi A; Coulibaly F; Rosenthal E; Subic-Levrero M; Roulot D; Zoulim F;
    JHEP Rep; 2024 Aug; 6(8):101057. PubMed ID: 39045338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection.
    Herta T; Hahn M; Maier M; Fischer J; Niemeyer J; Hönemann M; Böhlig A; Gerhardt F; Schindler A; Schumacher J; Berg T; Wiegand J; van Bömmel F
    Pathogens; 2022 Apr; 11(5):. PubMed ID: 35631038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; Scholtes C; Holzmann H; van Bömmel F; Borghi M; Perbellini R; Rimondi A; Farina E; Trombetta E; Manunta M; Porretti L; Prati D; Ceriotti F; Zoulim F; Bertoletti A; Lampertico P
    J Hepatol; 2022 Feb; 76(2):464-469. PubMed ID: 34699951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of bulevirtide in patients with chronic hepatitis D and compensated cirrhosis].
    Bogomolov PO; Ivashkin VT; Bueverov AO; Maev IV; Sagalova OI; Sleptsova SS; Yushuk ND; Gusev DA; Zhdanov KV; Chulanov VP
    Ter Arkh; 2021 Nov; 93(11):1290-1299. PubMed ID: 36286651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.
    El Messaoudi S; Brichler S; Fougerou-Leurent C; Gordien E; Gerber A; Kortebi A; Lagadic G; Subic-Levrero M; Metivier S; Pol S; Minello A; Ratziu V; Leroy V; Mathurin P; Alric L; Coulibaly F; Pawlotsky JM; Zoulim F; de Lédinghen V; Guedj J;
    JHEP Rep; 2024 Aug; 6(8):101070. PubMed ID: 39100818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study.
    Jachs M; Schwarz C; Panzer M; Binter T; Aberle SW; Hartl L; Dax K; Aigner E; Stättermayer AF; Munda P; Graziadei I; Holzmann H; Trauner M; Zoller H; Gschwantler M; Mandorfer M; Reiberger T; Ferenci P
    Aliment Pharmacol Ther; 2022 Jul; 56(1):144-154. PubMed ID: 35514008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
    Lampertico P; Roulot D; Wedemeyer H
    J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
    Degasperi E; Anolli MP; Lampertico P
    Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
    J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.